Author's response to reviews

Title: Drug Utilization Evaluation of Cefepime in the First Affiliated Hospital of Bengbu Medical College: A Retrospective and Prospective Analysis

Authors:

Shi Qingping (sir_shi@126.com)
Ding Feng (958387264@qq.com)
Sang Ran (13855288331@163.com)
Liu Yan (1055237127@qq.com)
Yuan Haoyu (302989860@qq.com)
Yu Meiling (yumeiling@sohu.com)

Version: 7 Date: 20 February 2013

Author's response to reviews: see over
February 20, 2013

Dr. Philippa Harris
Executive Editor

BMC Infectious Diseases

MS: 8337806207650699 -Subject: Submission of manuscript of “Drug Use Evaluation of Cefepime in the First Affiliated Hospital of Bengbu Medical College: A Retrospective and Prospective Analysis”.

Dear Dr. Harris,

I was very glad to receive your letter. Thank you very much for the report of the reviewers and your patience. I would like to provide this cover letter giving a point-by-point response to the concerns raised.

**Reviewer: P Ravi Shankar**

1. Page 6, what do the authors mean by sub-DTC?
   The term “sub-DTC” was replaced by “the sub-committee of the DTC, the Antibacterial Drug Management Team” in the manuscript.

2. Page 8, I was not able to understand what exactly the authors meant by life index record and solvent selection.
   We have made the following adjustments in the text:
   life index record (including basic patient characteristics such as height, body weight, body temperature, blood pressure, etc.)
   solvent selection (the choice of what kind of IV solution to use as the carrier of the cefepime infusion)

3. Page 12, paragraph 1, the word ‘sensitive’ should be changed to ‘sensitivity’.
   The word "sensitive" was changed to "sensitivity" in the manuscript.

4. Page 12, paragraph 2. The bacteria become resistant to the drug and not vice versa.
   The sentence should be corrected.
We have corrected the sentence to read “The following bacteria are associated with varying degrees of resistance to cefepime: *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Streptococcus faecalis*, some even up to 100%, and *Acinetobacter baumannii* and *Escherichia coli* up to 97.3%[17,18].”

5. Page 12, paragraph 2. What is meant by bauman acinetobacter?
The term “bauman acinetobacter” was replaced by “*Acinetobacter baumannii*” in the manuscript.

6. I did not understand the sentence beginning with ‘with cefepime as the specific control antibiotic’.
The phrase “with cefepime as the specific control antibiotic” was replaced by “with cefepime as the specific designated antibiotic drug” in the manuscript.

7. Page 14, paragraph 1. I do not think ‘avid’ is the appropriate word.
The word "avid" was changed to "positive" in the manuscript.

8. In the methods section, some more details of the professional training program is required. Who were the professionals trained, how were they trained, what were the topics of the training and how was the training delivered?
The sentence “To promote standardization in the management and clinical use of cefepime, clinical pharmacists and infectious disease experts carried out a number of these trainings for clinicians about the knowledge and clinical use of antibacterial drugs and their management through the organization of a sub-committee of the DTC, the Antibacterial Drug Management Team.” was added into the manuscript.

9. References should be written strictly according to the journal’s criteria.
References have now been written strictly according to the journal’s criteria.

10. In table 1, the total number of patients involved in cycle A and cycle B can be mentioned in the headings of columns 2 and 3.
This has been done, as requested.

**Reviewer:** Jason Roberts

Nil
Reviewer: Editors

1. Please clarify within your methods section if informed consent was obtained from patients for the prospective study.

Informed consent was not conducted in the study.

2. Please include the details of the specific ethics committee that approved your study within the methods section.

This survey was performed in accordance with the Helsinki Declaration and laws concerning privacy protection; no specific ethics committee approval was obtained, as the study was approved by the Department of Health of Anhui Province in China.

3. Please also ensure that your revised manuscript conforms to the journal style (http://www.biomedcentral.com/info/ifora/medicine_journals). It is important that your files are correctly formatted.

The revised manuscript was modified according to the sample article of the journal.

The above documents have been submitted in electronic version to BMC Infectious Diseases. If you have any questions or queries, please write to me by the email given below. I look forward to acknowledged receipt of this article by email.

Thank you very much.

Yours sincerely,

Qingping Shi

Department of Pharmacy,
The First Affiliated Hospital of Bengbu Medical College,
Bengbu 233004, China.

Email: sir_shi@126.com

Tel: +86-552-3086246.